Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | PRKDC | P78527 | 1/20 | 0.61 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25682967 | 0.92 | PIK3CA (0.51) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30434461 | 0.88 | PIK3CA (0.70) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL25674035 | 0.88 | PIK3CA (0.70) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24912818 | 0.87 | PIK3CA (0.72) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24912829 | 0.87 | PIK3CA (0.72) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30322552 | 0.87 | PIK3CA (0.61) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL26997603 | 0.86 | PIK3CA (0.68) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30322711 | 0.86 | PIK3CA (0.61) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL24913414 | 0.85 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 | |
| SCHEMBL30216301 | 0.85 | PIK3CA (0.65) | PIK3CAPIK3CBMTORPRKDCPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| EP-4444714-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118742545-A | Fused heterocyclic compounds as PI3K alpha inhibitors | 南京征祥医药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-11878970-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| US-20230096175-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878970-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885PIK3CB 16/4885MTOR 22/4885 |
| US-20230096175-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885PIK3CB 16/4885MTOR 22/4885 |
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885MTOR 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.